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Abstract: In an effort to study the effects of flexibility on enzyme recognition and activity, 
we have developed several different series of flexible nucleoside analogues in which the 
purine base is split into its respective imidazole and pyrimidine components. The focus of 
this particular study was to synthesize the truncated neplanocin A fleximers to investigate 
their potential anti-protozoan activities by inhibition of S-adenosylhomocysteine hydrolase 
(SAHase). The three fleximers tested displayed poor anti-trypanocidal activities, with EC50 
values around 200 μM. Further studies of the corresponding ribose fleximers, most closely 
related to the natural nucleoside substrates, revealed low affinity for the known T. brucei 
nucleoside transporters P1 and P2, which may be the reason for the lack of trypanocidal 
activity observed. 
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1. Introduction 
Modified nucleosides, in particular carbocyclic nucleosides, are potent inhibitors of S-adenosyl 
homocysteine hydrolase (SAHase) [1]. SAHase is a critical enzyme that hydrolyzes S-adenosyl 
homocysteine, the byproduct of biomethylations that utilize S-adenosylmethionine (SAM) [2,3].  
By inhibiting SAHase, an excess of SAH is produced, which in turn exhibits potent inhibitory effects 
on methyltransferases [4]. Thus, inhibition of SAHase leads to incomplete methylation of nucleic acids, 
phospholipids, proteins, and other small molecules, disrupting various biochemical pathways [5]. As a 
result, carbocyclic nucleosides have proven useful in a number of chemotherapeutic applications [6–8]. 
Neplanocin A (NpcA, Figure 1) and aristeromycin (Ari) are both naturally occurring carbocyclic 
adenosine analogues that have shown significant antiviral, antiparasitic and anticancer properties [4,7,9,10]. 
Unfortunately, NpcA and Ari both exhibit deleterious cytotoxicity due to intracellular conversion to 
their triphosphate forms by adenosine kinase as well as their recognition and metabolism by adenosine 
deaminase [11–13]. Removal of the 4'-CH2OH from Ari and NpcA, as shown in the truncated 
analogues shown in Figure 1 (R = H), significantly lowers the cytotoxicity [14]. 
Figure 1. Neplanocin A (NpcA) and analogues and the target NcpA fleximers (1–3). 
 
Interestingly, nucleosides with base modifications such as 3-deazaadenosine have also been found 
to act as substrates, with similar Km’s found for adenosine and 3-deazaadenosine [7,10,15]. To date, the 
truncated 3-deaza analogues of Ari and NpcA (truncated DZNepA, Figure 1) lacking the 4'-hydroxy-
methyl group have both exhibited greater levels of inhibition than their parent counterparts [5,6,13,16]. 
More importantly, these compounds have also shown potent inhibition against chloroquine-resistant 
and chloroquine-susceptible strains of P. falciparum [5]. In protozoan parasites, methylation of the 
four nucleosides present in the “cap-four” terminal end of mRNA requires SAM as the methyl donor. 
This cap structure is important for RNA recognition and stability, is highly conserved across almost all 
protozoan species, and is critical for replication [17–19]. Thus, inhibition of SAHase results in an 
accumulation of SAH, causing methylations to cease, which then disrupts the methylation of the cap 
structure, thereby providing an important target for the development of potential antiparasitic 
chemotherapeutics [5]. 
The Seley-Radtke group has long been interested studying the effects of flexibility on the nucleobase. 
This flexibility is achieved by “splitting” the purine base into its respective imidazole and pyrimidine 
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(or pyridine) components, which remain connected by a single carbon-carbon bond between the two 
heteroaromatic moieties. This connectivity allows for free rotation, while still retaining the elements 
essential for base pairing and molecular recognition [20–28]. This modification has led to enhanced 
enzyme binding and recognition, as well as the ability to overcome point mutations in enzyme binding 
sites [29,30]. These analogues have also been studied for their potential therapeutic properties [20–28]. 
Interestingly, when the fleximer analogues of adenosine (Flex-A), inosine (Flex-I) and guanosine 
(Flex-G) were studied in SAHase, which is a flexible enzyme, Flex-A and Flex-I acted as substrates, 
whereas Flex-G proved to be an inhibitor [22]. This is significant because it is, to our knowledge, the 
only report of a G-nucleoside inhibiting an adenosine metabolizing enzyme. It has been postulated that 
this is due to an intramolecular hydrogen bond between the pyrimidine and the 5'-OH of the sugar, 
which then positions the amino group into the binding site where the amino group on adenosine would 
normally reside, thus essentially creating an adenosine mimic [22]. 
Historically, a number of nucleoside analogues have been evaluated for trypanocidal activity [31–34]. 
For example, Cai et al. showed that the antiviral drug ribavirin was an inhibitor of Trypanosoma cruzi 
SAHase [33]. Additionally, 7-deaza-5'-noraristeromycin was shown to be a potent inhibitor of four 
strains of Trypanosoma brucei [34]. To further explore the potential of base flexibility and antiparasitic 
activity, we combined the fleximer base with the carbocyclic nucleoside scaffold, to determine whether 
the flexible base motif would enhance the biological results previously observed with carbocyclic 
analogues such as NpcA and Ari. Thus, a series of 3-deaza fleximers (compounds 1–3, Figure 1) were 
designed and synthesized to evaluate their anti-parasitic properties. 
2. Results and Discussion 
2.1. Chemistry 
As shown in Scheme 1, cyclopentenol 5 was available from known literature procedures starting 
from D-cyclopentenone 4 [35], which can be obtained following stereospecific reduction to the “down” 
hydroxyl using Luche reduction conditions [36]. Alcohol 5 was then coupled to 4,5-diiodoimidazole [29] 
using standard Mitsunobu [37] conditions to give 6. Initially the Mitsunobu reaction was attempted 
with diisopropylazodicarboxylate (DIAD) and triphenylphosphine (TPP) in dichloromethane  
at room temperature to yield 5, however only in a 12% yield. Attempts at heating the reaction only 
served to give additional side products, as well as to lower the yield even further. Changing the solvent 
to THF increased the solubility of the diiodoimidazole and subsequently resulted in an improved yield 
of 40%. Unfortunately, contaminates from the byproduct, triphenylphospine oxide (TPPO),  
still proved to be problematic during purification. Altering the phosphine reagent to DPPE  
(1,2-bis(diphenylphosphino)ethane) drastically improved the ease in purification. Other coupling 
methods were also tried, such as using Hendrickson’s “POP” reagent, bis(triphenyl)oxodiphosphonium 
trifluoromethanesulfonate [38], or using bases such as NaH or K2CO3[39] to form the imidazole 
nucleophile, proved unsuccessful when compared to the Mitsunobu coupling using DPPE. 
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Scheme 1. Synthesis of compound 6. 
 
Reagents and Conditions: a. CeCl3·7H2O, MeOH, NaBH4; b. DPPE, DIAD, 4,5-diiodoimidazole, THF, rt. 
Next, as shown below in Scheme 2, removal of the 5-iodo group of 6 to give compound 7 was 
achieved via selective deiodination using ethyl magnesium bromide (EtMgBr) followed by quenching 
with water. Coupling to the pyridine ring was then accomplished using Stille [40] coupling. 
Scheme 2. Synthesis of compounds 1–3. 
 
Reagents and Conditions: a. EtMgBr, THF, 0 °C; b. 3-tributyltin-2-chloropyridine, Pd(PPh3)4, 
Cu(I) Br, 1,4-dioxane, reflux; c. for compound 9: (i) hydrazine neat, 80 °C; (ii) TiCl3; for 
compound 10: concentrated acetic acid neat, 110 °C; d. TFA/H2O (1/1) in THF. 
The 3-tributyltin-2-chloropyridine was prepared from the commercially available 3-bromo-2-
chloropyridine. Stille coupling of 7 with the 3-tributyltin-2-chloropyridine provided 8 in a 23% yield, 
however when copper (I) bromide was used, the yield improved to 71%. Following Stille coupling, 
transformation of the chloro group into the exocyclic amine group was necessary. Standard procedures 
using MeOH/NH3 or converting the chloro to an azide using sodium or lithium azide proved 
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unsuccessful. A literature search revealed a palladium-assisted method developed by Hartwig using sodium 
t-butoxide in ammonia saturated 1,4-dioxane [41]. Unfortunately this method also proved unsuccessful. 
Related to this latter route, Buchwald developed a similar method, where the catalyst is made in situ 
using a more common phosphine ligand [42]. This method seemed promising since one of the 
examples utilized 2-chloropyridine, which was successfully converted in a 96% yield [28], but it too 
proved to be unsuccessful. Use of NaNH2 in ammonia was also tried but the conditions proved to be 
too harsh and decomposition ensued [43]. Another approach involved converting the chloro group 
using hydrazine followed by reduction. Initial attempts at reducing the hydrazine employed zinc in 
acetic acid, but this resulted in a complex mixture that could not be purified. Using titanium chloride 
(TiCl3) [44] proved to be successful, although there was evidence of some isopropylidene deprotected 
product(s) as well as protected products, thus treatment of the mixture with dilute TFA in THF gave 
the desired final product 1. 
Next, deaminated compound 10 was obtained from 8 using concentrated acetic acid at high 
temperature. Although this conversion also led to partial deprotection of the isopropylidene on the  
2'- and 3'-hydroxyls, the protected pyridine 10 was the major product. Subsequent deprotection of the 
isopropylidene of 10 led to the fleximer inosine 3. 
2.2. Trypanosomiasis Screening 
The three NpcA fleximers (1–3) were tested for trypanocidal activity against the laboratory 
Trypanosoma brucei brucei strain Lister 427, using a standard protocol based on the fluorescent format 
of 23 doubling dilutions, starting at 500 μM, in 96-well plates. All three fleximers tested displayed very 
similar activities against this strain, with EC50 values around 200 μM; in contrast, the control drug 
pentamidine displayed activity in the low nM range (Table 1), consistent with previous results [45,46]. 
Table 1. Trypanosomiasis results. 
Compound Average EC50 (µM) 
1 216 ± 21 
2 212 ± 31 
3 287 ± 24 
pentamidine 0.0044 ± 0.0001 
EC50 = concentration of drug required to give a 50% response. Data are the average of three independent 
experiments and SEM. 
We considered that the relatively low activity might be related to a lack of recognition of these 
molecules by the T. brucei nucleoside transporters. We therefore investigated whether fleximers in 
general display reduced uptake kinetics in these parasites, compared to their fixed-ring counterparts 
(Figure 2). Using the fleximers [21] most closely related to the original nucleoside substrates, it is clear 
from Table 2 that fleximers indeed show low affinity for the known T. brucei nucleoside transporters 
P1 and P2 [47]. 
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Figure 2. Transport of 0.1 µM [3H]-adenosine by Trypanosoma brucei brucei bloodstream 
form parasites. 
 
Table 2. Comparison of affinity of purine nucleosides and corresponding fleximers for  
T. brucei transporters. 
 
 P1 Ki (μM) P2 Ki (µM) 
 Nucleoside 1 Fleximer δ(ΔG0) Nucleoside 1 Fleximer δ(ΔG0) 
Adenosine 0.36 ± 0.05 35 ± 11 11.4 0.91 ± 0.29 37 ± 3 9.2 
Guanosine 1.8 ± 0.3 251 ± 75 12.2 >500 >500  
Inosine 0.44 ± 0.10 387 ± 30 16.8 >500 >500  
Data are the average inhibition constants (Ki) and SEM of at least three independent experiments; Values for 
adenosine are Michaelis-Menten constants (Km). 1 values were taken from previous findings of De Koning [47] 
and included here for comparison; δ(ΔG0) is the difference in Gibbs free energy of interaction of the 
nucleoside and the fleximer with the transporter, given in kJ/mol. 
Transport, mediated by the P1 nucleoside transporter, was measured in the presence or absence of 
various concentrations of nucleosides (filled symbols) or their corresponding fleximers (open 
symbols), in the presence of 100 µM adenine to block potential adenosine transport through the P2 
transporter. Data shown are the average and SEM of triplicate determinations in a single experiment, 
representative of three independent experiments with essentially identical outcomes. 
It is thus clear that the fleximers generally display about two orders of magnitude less affinity for 
the T. brucei nucleoside transporters than the corresponding nucleosides, limiting cellular uptake as 
there are no other nucleoside uptake mechanisms in these parasites than the P1 and P2 systems, 
although P1 consists of a cluster of multiple genes with slightly divergent sequences [48,49]. In 
addition, the truncated NpcA fleximers lack a 4'-hydroxymethyl group and an equivalent of the purine 
N3 residue, and both required for high affinity for P1 [50]. Moreover, the P2 transporter does not 
recognize any oxopurine nucleoside analogues [47]. The loss of approximately 10 kJ/mol in Gibbs free 
energy for the fleximer-transporter interaction may in part be due to the increased entropy in the 
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orientation of the fleximer orientation in the binding pocket, as well as the slightly larger volume of the 
base. We thus conclude that the low effectiveness of the Npc fleximers is at least partially due to 
unfavorable interactions with the parasite’s nucleoside transporters. As important differences exist 
between nucleoside transporters of even closely related pathogenic parasites including Trypanosoma 
congolense [51] and Leishmania species [48], it would be worthwhile to follow this study with a wider 
screening of anti-parasite activity for a diverse panel of protozoa. 
3. Experimental Section 
3.1. General Information 
All chemicals were obtained from commercial sources and used without further purification unless 
otherwise noted. Anhydrous DMF, MeOH, DMSO and toluene were purchased from Fisher Scientific 
(Pittsburgh, PA, USA). Anhydrous THF, acetone, CH2Cl2, CH3CN and ether were obtained using a 
solvent purification system (mBraun Labmaster 130, MBRAUN, Stratham, NH, USA). 3-Bromo-2-
chloropyridine was obtained from Sigma-Aldrich (St. Louis, MO, USA). Melting points are 
uncorrected. NMR solvents were purchased from Cambridge Isotope Laboratories (Andover, MA, 
USA). All 1H- and 13C-NMR spectra were obtained on a JEOL ECX 400 MHz NMR, operated at 400 
and 100 MHz respectively, and referenced to internal tetramethylsilane (TMS) at 0.0 ppm. The spin 
multiplicities are indicated by the symbols s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q 
(quartet), m (multiplet), and b (broad). Reactions were monitored by thin-layer chromatography (TLC) 
using 0.25 mm Whatman Diamond silica gel 60-F254 precoated plates. Column chromatography was 
performed using silica gel (63–200 µm) from Dynamic Adsorptions Inc. (Norcross, GA, USA), and 
eluted with the indicated solvent system. Yields refer to chromatographically and spectroscopically 
(1H- and 13C-NMR) homogeneous materials. High resolution mass spectra were recorded at the Johns 
Hopkins Mass Spectrometry Facility (Baltimore, MD, USA) using fast atom bombardment for ionization. 
3.2. Synthesis 
Preparation of (4R,5R)-4,5-O-isopropylidene-2-cyclopenten-1-ol (5): (4R,5R)-4,5-O-isopropylidene-2-
cyclopentenone 4 [35] (4.63 g, 0.03 mol) was dissolved in dry methanol (20 mL) at room temperature. 
CeCl3·7H2O was added to the reaction followed by the portionwise addition of NaBH4 (1.36 g,  
0.04 mol). Once TLC analysis showed the complete disappearance 4, the reaction was extracted into 
ethyl acetate (50 mL) and washed with water (10 mL). The organic layer was dried over MgSO4 and 
the solvent was removed under rotary evaporation. The crude oil was used in the following reaction 
without further purification. 
Preparation of (1′R,2′S,3′R)-1-[(2′,3′-O-isopropylidene)-4′-cyclopenten-1′-yl]-4,5-diiodoimidazole (6): 
Thoroughly dried 5 (0.78 g, 0.05 mol) was dissolved in dry THF (100 mL) under N2. 
Ethylenebis(diphenylphosphine) (2.0 g, 0.05 mol) and 4,5-diiodoimidazole (3.2 g, 0.01 mol) added to 
the reaction, followed by the dropwise addition of diisopropyl azodicarboxylate. The reaction was 
allowed to stir for 48 h and then the solvent was removed using reduced pressure. The crude material 
was purified by silica gel column chromatography hexanes–ethyl acetate (2:1) to yield a yellow waxy solid 
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(0.95 g, 0.02 mol, 41% yield). 1H-NMR (CDCl3): δ 1.32 (s, 3H), 1.45 (s, 3H), 4.44 (d, 1H, J = 5.5 Hz), 
5.24 (d, 1H, J = 1.4 Hz), 5.31 (m, 1H), 5.90 (dt, 1H, J = 4.6, 5.9 Hz), 6.34 (dt, 1H, J = 1.8 Hz, 5.9 Hz), 
7.38 (s, 1H). 13C-NMR (CDCl3): δ 25.9, 27.4, 70.8, 82.7, 84.2, 84.3, 97.1, 112.6, 128.9, 139.0, 139.4. 
HRMS calculated for C11H12I2N2O2 [M+H]+ 458.9066, found 458.9073. 
Preparation of (1′R,2′S,3′R)-1-[(2′,3′-O-isopropylidene)-4′-cyclopenten-1′-yl]-4-iodoimidazole (7): 
Dried 6 (1.83 g, 0.004 mol) was dissolved in anhydrous THF under N2. The reaction was dropped  
to 0 °C, and ethyl magnesium bromide (3.0 M, 1.3 mL, 0.004 mol) was added dropwise to the reaction. 
After 1 h the reaction was quenched with saturated NH4Cl (5 mL) and then the solvent was removed. 
The crude mixture was dissolved in ethyl acetate (50 mL) and washed with water (20 mL) and then 
dried over MgSO4. The solvent was removed under reduced pressure and purified using silica gel 
chromatography petroleum ether–ethyl acetate (2:1) to yield a yellow oil (1.12 g, 0.003 mol, 85% yield). 
1H-NMR (CDCl3): δ 1.28 (s, 3H), 1.40 (s, 3H), 4.44 (d, 1H, J = 5.5 Hz), 5.15 (d, 1H, J = 1.4 Hz), 5.30 
(dq, 1H, J = 1.8, 5.5 Hz), 5.87 (dt, 1H, J = 0.9, 5.5 Hz), 6.22 (dt, 1H, J = 1.8, 5.9 Hz), 6.89 (d, 1H,  
J = 1.4 Hz), 7.34 (d, 1H, J = 1.4 Hz). 13C-NMR (CDCl3): δ 25.7, 27.3, 68.3, 82.7, 84.2, 84.9, 112.5, 
123.2, 129.8, 137.5, 138.1. HRMS calculated for C11H13IN2O2 [M+H]+ 333.0100, found 333.0010. 
Preparation of 3-tributylstannyl-2-chloropyridine: Commercially available 3-bromo-2-chloropyridine 
(0.30 g, 0.002 mol) was dissolved in anhydrous THF (20 mL) under N2. Ethyl magnesium bromide  
(3.0 M, 0.5 mL, 0.002 mol) was added dropwise at room temperature. The reaction was allowed to stir 
for 2 h, and then tributyltin chloride (0.42 mL, 0.002 mol) was added and the reaction was left to stir 
overnight. The reaction was concentrated in vacuo and then purified on silica gel chromatography 
hexanes-ethyl acetate (15:1) to yield a colorless oil (0.40 g, 0.001 mol, 64% yield). 1H-NMR (CDCl3): 
δ 1.13 (m, 5 H), 1.30 (m, 13H), 1.56 (m, 6 H), 1.65 (m, 3 H), 7.13 (dd, 1H, J = 4.6, 7.8 Hz), 7.67 (dd, 
1H, J = 1.8, 4.6 Hz), 8.27 (dd, 1H, J = 1.8, 7.8 Hz). 13C-NMR (CDCl3): δ 26.9, 27.0, 27.3, 27.9, 28.9, 
29.0, 29.1, 122.2, 139.5, 146.9, 147.1, 147.2, 149.6, 159.2. 
Preparation of (1′R,2′S,3′R)-3-[((2′,3′-O-isopropylidene)-4′-cyclopenten-1′-yl)-(imidazol-4-yl)]-2-
chloropyridine (8): Intermediate 7 (0.34 g, 0.001 mol) and 2-chloro-3-(tributylstannyl)pyridine (3.50 g, 
0.007 mol) were dissolved in 1,4-dioxane under N2. Pd(PPh3)4 (0.05 g, 0.04 mmol) and CuBr (0.08 g, 
0.5 mmol) were added to the reaction and the reaction and was refluxed at 120 °C for 12 h. The 
reaction was cooled and filtered through a pad of Celite. The filtrate was diluted in ethyl acetate (20 mL) 
and washed with a saturated solution of NH4Cl (20 mL), water (20 mL), brine (20 mL) and then dried 
over MgSO4. The organic solvent was removed under reduced pressure and the crude material was 
purified using 5% MeOH in CH2Cl2 to yield a yellow oil (0.23 g, 0.7 mmol, 71% yield). 1H-NMR 
(CDCl3): δ 1.36 (s, 3H), 1.48 (s, 3H), 4.58 (d, 1H, J = 5.5 Hz), 5.28 (d, 1H, J = 1.4 Hz), 5.40 (dt, 1H,  
J = 0.9, 4.6 Hz), 6.00 (dd, 1H, J = 1.2, 5.5 Hz), 6.32 (dt, 1H, J = 1.8, 5.5 Hz), 7.30 (dd, 1H, J = 4.6, 7.7 Hz), 
7.55 (d, 1H, J = 1.4 Hz), 7.67 (d, 1H, J = 0.9 Hz), 8.26 (dd, 1H, J = 1.8, 4.6 Hz), 8.50 (dd, 1H, J = 1.8, 
7.8 Hz). 13C-NMR (CDCl3): δ 25.7, 27.3, 68.5, 84.4, 85.1, 112.6, 118.5, 122.8, 129.4, 130.1, 132.1, 
135.9, 136.9, 137.7, 137.9, 147.2. HRMS calculated for C16H16ClN3O2 [M+H 35Cl]+ 318.1009,  
[M+H 37Cl]+ 320.0980, found, 318.1001, 320.0976. 
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Preparation of (1′R,2′S,3′R)-3-[((2′,3′-O-isopropylidene)-4′-cyclopenten-1′-yl)-(imidazol-4-yl)]-2-
pyrimidone (10): Analogue 9 (0.1 g, 0.3 mmol) was dissolved in concentrated acetic acid in a sealed 
glass tube and heated to 120 °C overnight. The acetic acid was evaporated and the crude material was 
extracted into ethyl acetate. Silica gel chromatography using ethyl acetate-acetone-methanol (6:1:1) 
yielded an off white solid (0.05 g, 0.2 mmol, 56% yield). 1H-NMR (DMSO-d6): δ 1.24 (s, 3H), 1.32  
(s, 3H), 4.41 (d, 1H, J = 6.9 Hz), 5.05 (d, 1H, J = 4.6 Hz), 5.98 (d, 1H, J = 5.9 Hz), 6.12 (dt, 1H,  
J = 2.3, 5.9 Hz), 6.26 (t, 1H, J = 6.4 Hz), 7.24 (d, 1H, J = 4.6 Hz), 7.65 (d, 1H, J = 0.9 Hz), 7.79  
(d, 1H, J = 1.4 Hz), 8.07 (dd, 1H, J = 1.8, 7.3 Hz), 11.78 (bs, 1H). 13C-NMR (DMSO-d6): δ 25.5, 27.3, 
67.4, 73.0, 78.9, 105.8, 117.6, 125.1, 131.0, 131.6, 132.9, 133.9, 136.7, 136.8, 136.9, 160.7. HRMS 
calculated for C16H17N3O3 [M+H]+ 300.1348, found 300.1342. 
Preparation of (1′R,2′S,3′R)-3-[(2ʹ,3ʹ-Dihydroxy)-4ʹ-cyclopenten-1ʹ-yl]-(imidazol-4-yl)-2-amino-pyridine 
(1): Compound 8 (80 mg, 0.25 mmol) was refluxed in hydrazine (2 mL) for 1 h. The solvent was 
removed under reduced pressure and the residue dissolved in THF (5 mL). Titanium (III) chloride  
(1.7 mmol, 0.5 mL, 20% in 3% HCl) was neutralized using NaOH (0.5 mL, 20%), and 0.6 mL of the 
solution was added dropwise to the reaction. The mixture was refluxed at 70 °C for 4 h, cooled to room 
temperature, and brought to pH > 10 using NaOH (20%) while cooling in an ice-bath. The solvents 
were removed under vacuum, and the product was extracted with CH2Cl2 (10 mL × 5). The organic layer 
was dried over MgSO4. The solvents were evaporated, and the crude material, 3-[((2', 3'-O-
isopropylidene)-4'-cyclopenten-1'-yl)-imidazol-4-yl]-2-aminopyridine (9), was used directly in 
preparation of 1. Crude 9 was dissolved in THF (5 mL) and TFA:H2O (1 mL:1 mL) was added 
dropwise. This was allowed to stir overnight at room temperature. The solvent was evaporated and  
co-evaporated with ethanol (3 × 5 mL) to yield an off-white solid (0.03 g, 0.1 mmol, 46% yield over  
2 steps). 1H-NMR (DMSO-d6): δ 3.93 (m, 1H), 4.45 (m, 1H), 4.96 (m, 1H), 5.08 (m, 1H), 5.14 (d, 1H, 
J = 6.9 Hz), 5.96 (dd, 1H, J = 1.4, 6.4 Hz), 6.11 (dt, 1H, J = 2.3, 6.4 Hz), 6.54 (dd, 1H, J = 5.0, 7.3 Hz), 
6.95 (bs, 2H), 7.59 (d, 1H, J = 0.9 Hz), 7.70 (dd, 1H, J = 1.8, 7.4 Hz), 7.78 (d, 1H, J = 1.0 Hz), 7.81 
(m, 1H). 13C-NMR (DMSO-d6): δ 67.6, 73.1, 78.6, 112.2, 112.5, 115.1, 132.9, 133.7, 136.2, 136.9, 
140.1, 146.5, 156.5 HRMS calculated for C13H14N4O2 [M+H]+ 259.1195, found 259.1193. 
Preparation of (1′R,2′S,3′R)-3-[(2ʹ,3ʹ-Dihydroxy)-4ʹ-cyclopenten-1ʹ-yl]-(imidazol-4-yl)-2-chloro-
pyridine (2): Intermediate 8 (0.16 g, 0.5 mmol) was dissolved in THF (5 mL) and TFA:H2O (1 mL:1 mL) 
was added dropwise. This was allowed to stir overnight at room temperature. The solvent was 
evaporated and co-evaporated with ethanol (3 × 5 mL). Column chromatography in 10% MeOH in 
CH3CN returned an off-white solid (0.12 g, 0.4 mmol, 86% yield). 1H-NMR (DMSO-d6): δ 3.90 (m, 1H), 
4.42 (m, 1H), 4.98 (m, 1H), 5.08 (m, 1H), 5.17 (d, 1H, J = 6.4 Hz), 6.00 (dd, 1H, J = 1.4, 5.9 Hz), 6.11 
(dt, 1H, J = 2.3, 5.9 Hz), 7.43 (dd, 1H, J = 4.6, 7.8 Hz), 7.77 (s, 1H), 7.80 (s, 1H), 8.22 (dd, 1H, J = 2.3,  
4.6 Hz), 7.81 (dd, 1H, J = 1.8, 7.8 Hz). 13C-NMR (DMSO-d6): δ 67.6, 73.0, 78.9, 119.0, 123.8, 129.9, 
132.7, 135.4, 137.1, 137.6, 137.9, 146.5, 147.5. HRMS calculated for C13H12ClN3O2 [M+H 35Cl]+ 
278.0696, [M+H 37Cl]+ 280.0667, found, 278.0689, 280.0668. 
Preparation of (1′R,2′S,3′R)-3-[(2ʹ,3ʹ-Dihydroxy)-4ʹ-cyclopenten-1ʹ-yl]-imidazol-4-yl)-2-hydroxypyridine 
(3): Intermediate 10 (0.08 g, 0.3 mmol) was dissolved in THF (5 mL) and TFA:H2O (1 mL:1 mL) was 
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added dropwise. This was allowed to stir overnight at room temperature. The solvent was evaporated and 
co-evaporated with ethanol (3 × 5 mL). Column chromatography in ethyl acetate–acetone–methanol–water 
(6:1:1:0.5) produced an off-white solid (0.03 g, 0.1 mmol, 43% yield). 1H-NMR (DMSO-d6): δ 3.82 
(d, 1H, J = 4.6 Hz), 4.43 (bs, 1H), 4.95 (m, 1H), 5.05 (m, 1H), 5.11 (d, 1H, J = 7.4 Hz), 5.97 (dd, 1H,  
J = 1.4, 5.9 Hz), 6.12 (dt, 1H, J = 2.8, 5.9 Hz), 6.29 (t, 1H, J = 6.9 Hz), 7.23 (d, 1H, J = 4.6 Hz), 7.65 
(d, 1H, J = 0.9 Hz), 7.80 (d, 1H, J = 1.4), 8.08 (dd, 1H, J = 2.3, 7.3 Hz), 11.73 (bs, 1H). 13C-NMR 
(DMSO-d6): δ 67.6, 73.1, 78.6, 112.2, 112.5, 115.1, 132.9, 133.7, 136.2, 136.9, 140.1, 146.5, 156.5 
HRMS calculated for C13H13N3O3 [M+H]+ 260.1035, found 260.1033. 
3.3. Anti-Trypanosome Activity 
In vitro activity against Trypanosoma brucei was determined using the Alamar blue (resazurin) 
assay for cell viability exactly as described [52]. Briefly, serial dilutions of test compounds were made 
in 96-well plates by serial passage of 100 μL of test compound (usually at 2 mM) to 100 μL of HMI9 
medium containing 10% fetal bovine serum (Invitrogen), using 2 rows, with the negative control 
values obtained from wells with 100 μL of medium without test compound. Serial dilutions with 
pentamidine isethionate (Sigma) were used as positive control. To each well, 100 μL of medium, 
containing 104 culture-adapted bloodstream T. b. brucei (strain Lister 427), was added and the plates 
were incubated at 37 °C for 48 h after which 20 μL 5 mM resazurin solution was added. Following a 
further incubation of 24 h at 37 °C, fluorescence was determined in a FLUOstar OPTIMA (BMG 
Labtech, Aylesbury, UK) fluorimeter with excitation and emission filters at 544 nm and 620 nm, 
respectively. EC50 values (the effective concentration reducing specific fluorescence by 50%) were 
calculated by nonlinear regression using the Prism 5 software package (GraphPad, La Jolla, CA, USA). 
3.4. Transport Assays 
Transport assays with bloodstream forms of T. b. brucei were performed exactly as described 
previously [53,54]. Briefly, transport was initiated by the addition of 100 µL of T. b. brucei 
bloodstream forms (107 cells/mL in assay buffer [53]) to 100 µL of [2,8,5'-3H]-adenosine 
(PerkinElmer, Waltham, MA, USA; 54.4 Ci/mmol) pre-mixed with up to 1 mM of test inhibitor in 
assay buffer. After exactly 10 s the mixture was centrifuged through an oil layer in a microfuge 
(13,000× g) and the microfuge tubes were flash-frozen in liquid nitrogen. Pellets were cut off and 
collected in scintillation tubes; after solubilisation in 2% SDS and addition of scintillation fluid, 
radioactivity was determined in a liquid scintillation counter. Inhibition data were fitted to a sigmoidal 
curve with variable slope (GraphPad Prism 5.0), allowing for the determination of EC50 values, from 
which inhibition constants (Ki) were calculated using the Cheng-Prusoff equation, and Gibbs Free 
Energy using ΔG0 = −RTln (Ki), as described [52]. 
4. Conclusions 
The strategy of the work presented herein was to potentially synthesize new and more potent 
inhibitors of SAHases, thereby disrupting mRNA capping in protozoa as a strategy towards new 
antiparasitic therapeutics. To this end, characteristics of known SAHase inhibitors such as neplanocin 
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and Aristeromycin were combined, and the nucleoside analogue was given enhanced flexibility using 
the “fleximer” approach, and added specificity by omitting the N3 equivalent nitrogen residue in the 
pyrimidine half of the fleximer base group. In addition, the 4'-CH2OH moiety was omitted to reduce 
general cytotoxicity [10,14]. The data, however, show that the resulting 3-deazaneplanocin fleximers 
(1–3) displayed only moderate activity in a standardized anti-protozoal test, against Trypanosoma brucei, 
despite the possibility of this species being vulnerable to inhibition of SAHase [55]. 
We have previously shown that the trypanocidal action of nucleoside and nucleobase analogues is 
either enabled or limited by their rate of uptake by specific transport proteins [52–54,56,57], and 
therefore investigated the effect of the fleximer modification on nucleoside transport. We found that 
the introduction of this modification of the purine ring reduces affinity, and thus presumably 
translocation rates, for both of the transport systems expressed in bloodstream T. brucei, and conclude 
that the lack of suitable transporters for these molecules causes (or at least contributes to) the observed 
lack of trypanocidal potency. However, we have also shown that purine transporters in other protozoan 
parasites, e.g., Toxoplasma gondii [58], Plasmodium falciparum [59], Leishmania donovani [48],  
and Trichomonas vaginalis (Natto and De Koning, unpublished data) all have very different  
substrate-specificity characteristics. Further studies with additional parasites, and the optimization of 
the inhibitors for enhanced uptake by the parasites, are in progress. 
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